Ferdinando R.
- Country
- Italy
- Department
- U.O.C. Oncologia
Research Overview
- Phase 2 Randomized Trial of Durvalumab Followed by Chemotherapy Versus Chemotherapy Followed by Durvalumab in Elderly Patients with Advanced NSCLC
- Phase III Study of Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven Unresectable or Metastatic Papillary Renal Cell Carcinoma
- Efficacy and Safety of Palbociclib and Fulvestrant in HR+/HER2- Advanced Breast Cancer Post-CDK4/6 Inhibitor Therapy: A Phase II Multicenter Study
Data & Insights
Has run more than one trial at 357 of 718 partner sites.
Specializations
Breast Cancer and Other Solid Tumours
Clinical research includes breast cancer, triple-negative breast cancer, hormone receptor-positive and HER2-negative disease, as well as metastatic non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, and urothelial carcinoma. The therapeutic focus extends to ovarian cancer, colorectal cancer, melanoma, and head and neck squamous cell carcinoma.
- Advanced and metastatic solid tumours
- Endocrine-responsive breast cancer
- Thoracic and genitourinary oncology
- Gastrointestinal and hepatobiliary malignancies
Research activity also covers targeted therapy, immunotherapy, and treatment strategies for recurrent or unresectable disease.
Hematologic Malignancies and Bone Marrow Failure
Investigational work spans acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, multiple myeloma, lymphoma, myelodysplastic syndromes, and myelofibrosis. The portfolio also includes myeloproliferative neoplasms and related anemia syndromes.
- Leukemia and lymphoma
- Plasma cell disorders
- Myelodysplastic and myeloproliferative disease
- Thalassemia and hemoglobinopathies
Therapeutic interests include novel anti-cancer agents, cellular therapy, and supportive approaches for transfusion-dependent and marrow-related cytopenias.
Autoimmune, Inflammatory, and Dermatologic Disease
Clinical research covers ulcerative colitis, Crohn’s disease, hidradenitis suppurativa, atopic dermatitis, psoriasis, prurigo nodularis, cutaneous lupus erythematosus, and juvenile idiopathic arthritis. Additional interests include myasthenia gravis, immune thrombocytopenia, and systemic autoimmune disorders.
- Inflammatory bowel disease
- Autoimmune skin disease
- Rheumatologic and neuromuscular autoimmunity
- Immune-mediated hematologic conditions
Therapeutic activity emphasizes immune modulation across chronic inflammatory disorders and organ-specific autoimmune disease.
Cardiovascular, Renal, and Metabolic Disorders
Research involvement includes atherosclerotic cardiovascular disease, heart failure, atrial fibrillation, myocardial infarction, hypertension, cardiomyopathy, and pulmonary arterial hypertension. The portfolio also extends to chronic kidney disease, IgA nephropathy, membranous nephropathy, and diabetic complications.
- Cardiometabolic risk reduction
- Heart failure and arrhythmia
- Kidney disease and glomerular disorders
- Diabetes-related vascular complications
Therapeutic interests include vascular prevention, renal protection, and treatment of metabolic dysfunction linked to cardiovascular and kidney disease.
Respiratory, Neurologic, and Rare Disease Therapies
Clinical activity also includes asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, pulmonary sarcoidosis, and bronchiectasis. Neurologic interests cover multiple sclerosis, epilepsy, migraine, Alzheimer’s disease, and Tourette’s disorder, alongside selected rare genetic and metabolic diseases.
- Airway and interstitial lung disease
- Neuroinflammatory and seizure disorders
- Neurodegenerative disease
- Inherited metabolic and hematologic rare disease
Research interests include biologic therapies, neurologic symptom control, and treatment options for chronic respiratory and rare systemic conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.